Skye Bioscience, Inc. Common Stock (SKYE) is a publicly traded Healthcare sector company. As of May 20, 2026, SKYE trades at $0.74 with a market cap of $27.33M and a P/E ratio of -0.52. SKYE moved +0.00% today. Year to date, SKYE is -17.42%; over the trailing twelve months it is -66.27%. Its 52-week range spans $0.57 to $5.96. Analyst consensus is buy with an average price target of $9.50. Rallies surfaces SKYE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Recent SKYE insider activity includes Schwab Andrew J. sold 163.98K, Schwab Andrew J. sold 6.47K, 5AM Partners VII, LLC sold 163.98K, 5AM Partners VII, LLC sold 6.47K, and Schwab Andrew J. sold 58.64K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
| Metric | Value |
|---|---|
| Price | $0.74 |
| Market Cap | $27.33M |
| P/E Ratio | -0.52 |
| EPS | $-1.41 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.96 |
| 52-Week Low | $0.57 |
| Volume | 48.16K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-55.92M |
| Gross Margin | 0.00% |
6 analysts cover SKYE: 0 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.50.